

45th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine Draft Program

FRIDAY 17 APRIL 2015 PRE-CONFERENCE SYMPOSIUM

Victoria Park, Herston Road, Herston

10:00: Welcome

10:10: The Increasing Role of MRI in Paediatric Oncology - *Dr David Lisle, Royal Brisbane Hospital and Brisbane Private Hospital*

10:40: PET/CT & MRI or PET/MRI in Paediatric Medicine. Where are we going? - *Professor Robert Howman-Giles, University of Sydney*

11:10: Morning tea

11:40: Evidence Based Medicine and Clinical PET/MRI - *Ken Miles, Princess Alexandra Hospital*

12:10: Multimodality imaging as fundamental tool - *Prof. Markus Schwaiger, Technische Universität München*

12:40: Lunch

13:40: Ga-68 A generator based PET nuclide - *Prof. Frank Rösch, Johannes Gutenberg-University Mainz*

14:10: Close

18:00 -19:00 Welcome Reception - Brisbane Convention and Exhibition Centre Plaza Level

SATURDAY 18 APRIL 2015 ANZSNM 2015 ASM

Brisbane Convention and Exhibition Centre Plaza Level

07:00 - 08:15: **Siemens Breakfast Session** - First local clinical experiences with xSPECT technology – A panel discussion with Prof Dale Bailey and A/Prof Michael Hofman.

Room: P9

07:30: Registration

08:30 - 10:00: **Plenary Session** - Room: Plaza Auditorium

08:15: Official Opening

08:30: **Plenary 1:** What's New in Nuclear Cardiology: Expanding Applications and Changing Paradigms, *Dr John Mahmarian, The Methodist Hospital*

09:15: **Plenary 2:** SPECT/CT for the diagnosis of benign and malignant diseases, *Assoc. Prof. Hojjat Ahmadzadehfar, University Hospital Bonn*

10:00: Morning tea

10:30 - 13:00: **Concurrent sessions 1A - 1D**

1A AANMS Symposium

Room: Plaza Auditorium

10:30: How Best to Stress My Patient: The Role of New Pharmacologic Stressor Agents
Dr John Mahmarian, The Methodist Hospital

140 O1

228 O2

1B Physics Symposium 1

Room: P9

10:30: Patient specific dosimetry of extravasation of radiopharmaceuticals using Monte Carlo
Steven Goodman, Royal Brisbane & Women's Hospital

10:45: Investigating the mixing of quality control phantoms using dynamic planar imaging and computational fluid dynamics
Darin O'Keeffe, Christchurch Hospital

1C Technologists' Symposium 1

Radpharm Award*

Room: P10

10:30: The changing role of the technologist
David Gilmore, SNMMI-TS

1D Radiopharmacy

Symposium 1

Room: P11

10:30: A generator-based PET nuclide ⁶⁸Ga and the new world of ⁶⁸Ga-PET radiopharmaceuticals
Univ.-Prof. Dr Frank Roesch, Johannes Gutenberg-University Mainz

11:00: Low dose PET Imaging for nutrition and metabolism studies <i>Prof. Dr Michael V. Knopp, Wright Center for Innovation</i>	232	O3	11:00: Assessment and correction of partial volume effect in SPECT/CT <i>Andrew Chicco, Department of Nuclear Medicine & PET, Liverpool Hospital</i>	256	O6*	11:00: Incremental value of SPECT/ CT over planar imaging in dacroscintigraphy <i>Leticia Burton, Concord Nuclear Imaging</i>	192	O14	11:00: The automated preparation, MicroPET/CT imaging, biodistribution and radiation dosimetry of 18F-labeled RGD peptide analogue (18F-AIF-RGD2) <i>Ming-Wei Wang, Fudan University Shanghai Cancer Center</i>
	213	O5	11:15: Dead time correction in Lu-177 DOTATATE therapy imaging <i>Casper Marciniak, St George Hospital</i>	102	O7*	11:10: McCune-Albright Syndrome, a rare occurrence <i>Lisa Xu, St. Vincent's Hospital, Melbourne</i>	199	O15	11:12: Dose-on-demand microfluidic radiopharmaceutical production for improving flexibility of preclinical studies <i>Giancarlo Pascali, ANSTO</i>
11:30: SPECT/CT for the treatment planning of radioembolization <i>Assoc. Prof. Hojjat Ahmadzadehfar University Hospital Bonn</i>	166	O42	11:30: Measuring Lu-177m contamination in Lu-177 <i>Daniel Badger, The Queen Elizabeth Hospital</i>	255	O8*	11:20: Erdheim-Chester Disease: A Very Rare Disease <i>Chris Travis, Queensland Xray</i>	106	O16	11:24: Preliminary investigation of a Gallium-68, Copper-64 and Lutetium-177 labeled PSMA targeting ligand for imaging and radionuclide therapy of prostate cancer <i>Peter Roselt, Peter MacCallum Cancer Centre</i>
				147	O9*	11:30: Splenosis post splenectomy: Something to watch out for! <i>Amy Evans, Sir Charles Gairdner Hospital</i>	118	O17	11:36: Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent <i>Amir R Jalilian, Radiation Application Research School</i>
				113	O10*	11:40: 99m-Tc-HMPAO labelled white cell scan in a patient with polycystic kidneys and end stage renal failure <i>Kari Hughes, Royal Adelaide Hospital</i>	160	O18	11:48: Site-specific enzymatic and click chemistry bioconjugation of metal complexes to single-chain antibodies for PET/CT imaging of activated platelets <i>Christoph Hagemeyer, Baker IDI Heart and Diabetes Institute</i>
				161	O11*	11:50: The value of 68Ga-PSMA PET/CT in detecting recurrent prostate cancer: A case study <i>Ingrid Holmes, The Royal Brisbane and Women's Hospital, Queensland Health</i>	175	O19	12:00: L-Tyrosine confers greater residualizing properties to a D-amino acid rich residualizing peptide for radioiodination of internalising antibodies <i>FT Lee, Olivia Newton-John Cancer Research Institute</i>

167 **O12*** 12:00: How old is too old for an MCU?
Trish Mead, Auckland District Health Board

178 **O20** 12:12: Optimizing pharmacokinetics and targeting properties of recombinant anti-Lewis Y antibody hu3S193 in A431 tumour-bearing mice
FT Lee, Olivia Newton-John Cancer Research Institute

150 **O13** 12:10: The set-up and Implementation of a PET/MRI System - a technologist's perspective
Tale Liiv & Michelle Jenkins, Princess Alexandra Hospital

12:00: **AANMS AGM**
13:00: Lunch

12:00: **Physics AGM**

12:30: **Technologists' AGM**

12:30: **Radiopharmacy AGM**

14:00 – 14:45: **Plenary Session** - Room: Plaza Auditorium

14:00: **Plenary 3:** PSMA PET for Management of Patients with Prostate Cancer, *Prof. Markus Schwaiger, Technische Universität München* Room: Plaza Auditorium

14:45: **Lowenthal Lecture**
Marissa L. Bartlett Room: Plaza Auditorium

14:45: **ARTnet**
Room: P9

15:30 Afternoon tea

16:00-17:30: **Concurrent sessions 2A - 2D**

2A AANMS Awards
Room: Plaza Auditorium

2B Physics Symposium 2
Room: P9

**2C Technologists' Symposium 2
Mallinckrodt Award***
Room: P10

**2D Radiopharmacy
Symposium 2**
Room: P11

144 **O21** 16:00: Quantitative sacroiliac joint scintigraphy using Tc99m-hydroxy-methylene diphosphonate (HDP)
Apurv Garg, The Canberra Hospital

229 **O26** 16:00: Initial evaluation of newly proposed L-SPECT system for SPECT imaging
Tasneem Rahman, UNSW Australia, Canberra

16:00: An Update on the MRPB Supervised Practice Program
Helen Tierney, Medical Radiation Practice Board of Australia

121 **O34** 16:00: Studies on specific activities (SA) of ¹⁷⁷Lu for labeling a preferred constant typical clinical dose of 0.2 mg [DOTA0,Tyr3]-octreotate (DOTATATE) with 11.1 GBq ¹⁷⁷Lu for Peptide Receptor Radionuclide Therapy (PRRT)
Wouter Breeman, Erasmus MC Rotterdam

146 **O22** 16:15: Normal range of osteoblastic activity in asymptomatic total hip arthroplasties (THA) on SPECT bone scintigraphy
Senpei Jin, Lake Imaging

176 **O27** 16:15: CT automatic exposure control techniques in ¹⁸F-FDG oncology PET CT imaging
Deborah Tout, Biomedical Technology Services

227 **O28*** 16:20: A comparison of SPECT/CT bone scan to MRI and planar scintigraphy in the evaluation of inflammatory back pain
Cynthia Prajogo, Concord Hospital

126 **O35** 16:12: In-house developed semi-automated kit for zirconium-89 (⁸⁹Zr) production
Soren Lummis, Medical Technology & Physics, Sir Charles Gairdner Hospital

- 156 **O23** 16:30: Adjuvant Administration of I-131 LIPIODOL IN HCC - A Single centre experience
Ruchit Mohindra, Queen Elizabeth Hospital
- 168 **O24** 16:45: Ga-68 DOTA-Octreotate (Gatate) and F-18 Fluorodeoxyglucose (FDG) PET/CT in the assessment of paragangliomas and pheochromocytomas
Chian Aun Chang, Peter MacCallum Cancer Centre
- 217 **O25** 17:00: Time-of-flight PET/CT in mediastinal staging of non small cell lung cancer
Yi-Tung Tom Huang, Department of Nuclear Medicine and PET, Liverpool Hospital
- 16:30 **IAEA UPDATE**
Uday Bhonsle, IAEA
- 143 **O29*** 16:32: Frequency of apparent peripheral bony uptake of Iodine-131 on whole body scans
Lauren Dorn, Royal Melbourne Hospital
- 189 **O30*** 16:44: Dual head geometric mean vs. single head posterior imaging for potential kidney donors
Joshua Eschebach, Westmead Hospital
- 248 **O31*** 16:56: Role of 68Ga-DOTATATE PET/CT in Detection of glomus tympanicum
My Linh Diep, Monash Health
- 186 **O32** 17:08: KARL100 and RadInject automated dose dispensing system: Initial experience and evaluation of staff dose reduction
Annah Skillen, Royal Free London NHS Foundation Trust
- 170 **O33** 17:20: Resolution recovery and its effect on differentiating bowel uptake in Myocardial Perfusion Scans
Sithoeun Sam, Nuclear Medicine Department, Liverpool Hospital
- 16:24: Update - Masters of Radiopharmaceutical Science)
Jennifer Guille, Andrew Katsifis Prince of Wales Hospital/Royal Prince Alfred Hospital
- 16:36: Update - Certification
Jennifer Guille, Andrew Katsifis Prince of Wales Hospital/ Royal Prince Alfred Hospital
- 16:48: Automated production of 68Ga radiopharmaceuticals - the RBHW experience using the Scintomics GRP® Synthesiser
Melissa Latter Royal Brisbane and Women's Hospital
- 17:00: RAPID Laboratory Highlights at Sir Charles Gairdner Hospital
Soren Lummis Sir Charles Gairdner Hospital
- 17:12: Site highlight from Peter MacCallum
Peter Roselt, Peter MacCallum Cancer Centre
- 17:24: Improving the Labelling Yield and Clinical Reliability of Electrophilic FDOPA
Stephen Taylor Royal Brisbane and Women's Hospital

17:30: Close

19:00: **NUC's Party**, AANMS Fellows' Dinner

Brisbane Convention and Exhibition Centre Plaza Level

07:00 - 08:15: **Insight Breakfast Session** - *Michael V. Knopp, M.D., Ph.D.* - Digital PET/CT: The next generation of Clinical PET systems? Room: P9

08:30-10:00: **Plenary** - Room: Plaza Auditorium

08:30: **Plenary 4:** The generator based PET nuclide ⁶⁸Ga and the therapeutic nuclide ¹⁷⁷Lu: The most efficient theranostic system in nuclear medicine, *Univ.-Prof. Dr Frank Roesch, Johannes Gutenberg-University Mainz*

09:15: **Plenary 5:** Redefining the clinical PET/CT acquisition by re-optimization of its components, *Prof. Dr Michael V. Knopp, Wright Center for Innovation*

10:00: Morning Tea

10:30-12:00 **Concurrent sessions 3A - 3B**

3A ONCOLOGY 1

Room: Plaza Auditorium

3B ANSTO AWARD*

Room: P10-11

3C NMT WORKSHOP 1

Room: P9

177 **O36** 10:30: Phase I safety and biodistribution study of ¹²⁴I-PEG-AVP0458 diabody in patients with TAG-72 positive ovarian and prostate cancer
Sze Ting Lee, Austin Health

201 **O41*** 10:30: Visual assessment of coronary calcification on the low dose CT for attenuation correction in myocardial perfusion Imaging, it's validity and reproducibility on patient's management
Raef Boktor, Lake Imaging, St John of God hospital

200 **O37** 10:45: The added value of ¹⁸-F Fluoride PET/CT bone scans over planar bone scintigraphy in detecting bone metastases from breast cancer patients and its impact on patient management
Randeep Kulshrestha, Central Manchester University Teaching Hospitals NHS Foundation Trust

141 **O43*** 10:45: Improved survival of poor prognosis FDG-avid neuroendocrine tumours with Lu-177 octreotate peptide receptor chemoradionuclide therapy (PRCRT)
Michael Hofman, Peter MacCallum Cancer Centre

10:45: Overview CPD and the new ANZSNM website
Liz Bailey / Andrew St John

251 **O38** 11:00: Prognostic role of metabolic parameters of ¹⁸F-FDG PET-CT scan performed during radiation therapy in head and neck squamous cell carcinoma
Peter Lin, Department of Nuclear Medicine and PET, Liverpool Hospital

ADVANCES IN NEUROLOGICAL PET
11:05: Contributions of PET to Clinical Neuroscience
Peter Herscovitch, MD, FACP, FRCPC, President, SNMMI

11:10: Update on the MRPB CPD Requirements
Mark Marcenko / Travis Pearson

195 **O39** 11:15: The lack of clinical impact of FDG PET-CT for early merkel cell carcinoma with concurrent sentinel lymph node biopsy staging
Jui Liu, Westmead Hospital

216 **O40** 11:30: Added value of diagnostic CT and MRI in breast cancer patients who have had 18F-Fluoride PET/CT bone scans
Randeep Kulshrestha, Central Manchester University Teaching Hospitals NHS Foundation Trust

11:30: Panel Discussion - Brainstorming session on CPD tools and activities for the new website - what for the members want?

12:00: **ANZSNM AGM** Room: Plaza Auditorium

13:00: Lunch

14:00-15:15 **Concurrent sessions 4A - 4B**

4A ONCOLOGY 2

Room: Plaza Auditorium

4B QUEENSLAND PERSPECTIVES

Room: P10-11

4C NMT WORKSHOP 2 - MENTOR WORKSHOP

Room: P9

208 **O44** 14:00: Cost effectiveness analysis of FDG PET/CT in advanced stage and recurrent / metastatic breast carcinoma
Salvatore Berlangieri, Austin Health

14:00: Ga-68 PSMA PET/CT at The Wesley Hospital, Brisbane
Dr David Wong

14:00: Welcome and Thank-you
Liz Bailey

139 **O45** 14:15: Comparison of the cost and radiation dose of Gallium 68-somatostatin analogue PET-CT with Indium-111 octreotide SPECT-CT in the WA public hospital setting
Tatiana Segard, Sir Charles Gairdner Hospital

14:20 Queensland Health New Technology Funding and Evaluation Programme - The PET/MRI project
Prof. Ken Miles

14:20: Future Role Professional Mentor
TSIG Committee Members

155 **O46** 14:30: Respiratory gating of FDG PET/CT in non-small cell lung cancer: Does lack of movement predicts pleural involvement
Suang Kiat Lau, Nuclear Medicine Department, Westmead Hospital

14:40: New research tracers and Human Research Imaging Facility at Royal Brisbane Hospital
Dr Paul Thomas

14:30 Panel Discussion - Should the society continue the Mentor program and how could it work?

174 **O47** 14:45: Clinical implementation of Siemens amplitude-based respiratory gating (HD Chest) for 18F-FDG oncology PET
Joseph Cotterill, Griffith University

15:00: Risky Business – Estimating Fracture Risk with DXA
Dr Joseph Wong

180 **O48** 15:00: Optimisation of routine clinical imaging protocols in 18F-FDG oncology PET CT imaging
Deborah Tout, Biomedical Technology Services

15:15-16:00: Afternoon tea. 15:30-16:00: Poster Walk

16:00-17:15 **Concurrent sessions 5A - 5B**

5A CARDIOLOGY & PULMONARY

Room: Plaza Auditorium

193 **O49** 16:00: Optimisation of dosage for myocardial perfusion imaging using an anthropometric formula
Greg Walker, Lake Imaging

153 **O50** 16:15: Review of nuclear cardiology practices and radiation exposure in the Oceania region: Results from the IAEA nuclear cardiology protocols study (INCAPS)
Sinjini Biswas, Royal Melbourne Hospital

142 **O51** 16:30: High resolution 68Ga ventilation-perfusion PET/CT for assessing lung function: comparison with pulmonary function tests
Pierre-Yves Le Roux, Brest University Hospital

191 **O52** 16:45: Current practices in pulmonary scintigraphy for pulmonary embolism diagnosis: an international survey in Australia, Canada and France
Pierre-Yves Le Roux, Brest University Hospital.

5B ONCOLOGY 3 / RENAL

Room: P10-11

184 **O53** 16:00: Impact of delayed imaging on interpretation of [68Ga]-PSMA PET in prostate cancer
Geoffrey Schembri, Royal North Shore Hospital

124 **O54** 16:15: Does PSA level predict the extent of [68Ga]-PSMA PET positive disease in prostate cancer patients with biochemical recurrence after radical prostatectomy
Geoffrey Schembri, Royal North Shore Hospital

148 **O55** 16:30: Ga-68 EDTA PET/CT to image renal function and assess glomerular filtration rate (GFR): comparison to plasma sampling including Cr-51 EDTA
Michael Hofman, Peter MacCallum Cancer Centre

182 **O56** 16:45: Identifying and locating parathyroid adenomas: Concordance between pinhole parathyroid scintigraphy and parathyroid surgery
Elizabeth Clingan, St George Hospital Nuclear Medicine Department

17:15: Close

19:00: Gala Awards Dinner

MONDAY 20 APRIL 2015

07:00 - 08:15: **PETNET Solutions Breakfast Session** – Assoc. Prof. Hojjat Ahmadzadehfar The role of PET/CT in treatment planning of radionuclide therapies. Room: P10-11

08:30-10:00: **Plenary** Room: Plaza Auditorium

08:30: **Plenary 6:** PET/MR for nuclear cardiology, *Prof. Markus Schwaiger, Technische Universität München*

09:15: **Plenary 7:** The Complementary role of CT and Nuclear Cardiac Imaging in Guiding Patient Management – Navigating in a Multimodality World, *Dr John Mahmarian, The Methodist Hospital*

10:00: Morning tea

10:30 – 11:15: **Pioneer Lecture** – Dr Emlyn Jones

11:15- 12:30 **Concurrent sessions 6A - 6B**

6A THERAPY

Room: Plaza Auditorium

157 **O57** 11:15: Single centre experience of therapeutic/palliative iodine-131 Lipiodol for HCC - Is there still a role for it?
Ruchit Mohindra, The Queen Elizabeth Hospital

219 **O58** 11:30: Lu-177 DOTATATE therapy in patients with NETs
Erika Hosking, Neuroendocrine Unit, St George Hospital, Kogarah

222 **O59** 11:45: Relationship between whole body clearance, kidney dose and GFR in [Lu-177]-DOTATATE therapy
Thomas Hennessy, School of Physics, University of Sydney

ADVANCES IN RHEUMATOLOGY IMAGING

12:00: New imaging approaches for diagnosis of arthritis and probable therapeutic options
Vijay Kumar, Sydney University

12:30-13:00: **Plenary** Room: Plaza Auditorium

12:30: **Conference Highlights** Dr Joseph Wong, Co-Convenor ANZSNM 2015

13:00: **Conference Close**

6B INFECTION/ NEUROLOGY

Room: P10-11

137 **O60** 11:15: The role of 18F-FDG PET/CT in paediatric acute multifocal osteomyelitis
Nadya Kisiel, The Children's Hospital at Westmead

165 **O61** 11:30: An earlier role for PET in the investigation of PUO? A 5-year retrospective cost benefit analysis
Mark Tang, Austin Health

194 **O62** 11:45: Characterising physiological conus uptake in [F18]-FDG PET/CT
Aileen Cormican, Department of Radiology & Molecular Imaging

POSTERS ROOM P6-P9

- 122 **P01** Octreotide or Dotatate. Is there any difference?
Stacey Johnson, Guy's and St Thomas Hospital
- 120 **P26** DMSA scan in atheroembolic renal disease
Angela Woodcock, Bankstown-Lidcombe Hospital
- 236 **P52** Hypercalcemia and its effect on the biodistribution of 99mTechnetium-Hydroxymethylene Diphosphonate (99mTc-HDP) in skeletal scintigraphy: A case study
Brittany Robinson, The Royal Brisbane and Women's Hospital
- 149 **P78** Are ventilation perfusion scans more common on Fridays?
Kelvin Yap, St. Vincent's Hospital Melbourne
- 123 **P02** Management impact of vesicular monoamine transporter (VMAT) imaging with [18F]AV133 in clinically uncertain Parkinsonian syndromes (CUPS)
Sarah Jesudason, Austin Health
- 205 **P27** Can acquisition time be shortened in Hepatobiliary scintigraphy following administration of Ensure Plus® to assess gallbladder ejection fraction?
Katrina Devitt, Royal North Shore Hospital
- 108 **P53** A rare case of metastatic papillary thyroid cancer to the breast and other soft tissues
Cynthia Prajogo, Concord Hospital Nuclear Medicine
- 212 **P79** GMP practices in a hospital radiopharmacy
Dominique Scott, Royal Brisbane and Women's Hospital
- 238 **P03** Prospective study of whole body FDG PET/CT in patients with polymyalgia rheumatica
Sze Ting Lee, Austin Health
- 163 **P28** Scintigraphic methods to rule out hepatic neoplasms
Luke Baker, The Townsville Hospital
- 117 **P54** Takotsubo cardiomyopathy: An incidental diagnosis on gated myocardial perfusion SPECT
Amir Iravani Tabrizipour, Sir Charles Gairdner Hospital
- 171 **P80** Patient factors affecting fluorodeoxyglucose (FDG) scan cancellations and minimisation strategies to prevent future occurrences
Stacey Skalkos, Nuclear Medicine & PET Department Liverpool Hospital
- 110 **P04** Emerging role of FDG-PET in the diagnosis of IgG4 related disease: A Case of multiorgan involvement
Amir Iravani Tabrizipour, Nepean Hospital
- 135 **P29** Development of simple colonic transit study protocol and analysis / display workflow using Siemens software and Excel
Jacky Maggs, Townsville Hospital
- 239 **P55** Fluoro-deoxy-glucose Positron Emission Tomography diagnosed small bowel intussusception due to Hodgkins lymphoma
Apurv Garg, The Canberra Hospital
- 129 **P81** Tools and strategies for improving the quality of clinical placements for nuclear medicine students
James Turner, The Royal Brisbane & Women's Hospital
- 207 **P05** The prevalence of extraskeletal findings on the unenhanced low dose CT component of the 18F-Fluoride PET/CT bone scan in breast cancer patients
Ruth Menghis, Royal Liverpool Hospital
- 196 **P30** Review of early and delayed imaging protocol following low dose radioiodine ablation - does it change sensitivity?
Andrew Cluff, Royal North Shore Hospital
- 188 **P56** A V/Q scan leading to the diagnosis of a bronchial neuroendocrine (atypical carcinoid) tumour
Reza Garzan, Eastern Health
- 253 **P82** New kids on the block
Shonika Scortechini, Royal Brisbane and Women's Hospital

203	P06	Follow-up studies of 18-F sodium fluoride PET/CT bone studies in patients with breast cancer bone metastases: Planar bone scintigraphy versus 18F-Fluoride PET/CT: Which are we doing and why? <i>Randeep Kulshrestha, Central Manchester University Teaching Hospitals NHS Foundation Trust</i>	116	P31	Emerging role of Bremstrahlung SPECT/CT imaging in yttrium-90 radiosynovectomy <i>Ali Mazar-Atabaki, Concord Hospital</i>	233	P57	Incidental finding of a large ovarian cyst on a whole body bone scan <i>Swenja Fischer, Southern Nuclear Imaging Group</i>	257	P83	Protecting Mission Critical Patient Data, Images and Servers with the Zettabyte File System <i>Peter Santos, Western Health and Access Medical Imaging</i>
190	P07	18F-fluoroethyl-tyrosine PET in differentiating recurrent glioma and radiation necrosis: A retrospective single center study <i>Amir Iravani Tabrizipour, Department of PET and Nuclear Medicine, Nepean Hospital, NSW</i>	218	P32	SPECT/CT SUV - Technologists experience using a commercially available software package <i>Eric Stoakes, Nuclear Medicine Department Liverpool Hospital</i>	114	P58	Disappearing bone disease (Gorham's disease) demonstrated on SPECT/CT imaging <i>Ali Mazar-Atabaki, Concord Hospital</i>	258	P84	A Novel Activity Calibration Technique for Alpha Emitting Radiopharma-Ceuticals Using Gafchromic EBT3® Radiochromic Film and a Densitometer <i>Uday Bhonsle, IAEA</i>
109	P08	Nervous system involvement by recurrence of non-Hodgkin Lymphoma on FDG-PET/CT: Leptomeningeal disease and neurolymphomatosis <i>Amir Iravani Tabrizipour, Nepean Hospital</i>	152	P33	The value of SPECT/CT in the characterisation of scan findings - from disease to physiological variant. <i>Belinda Vaughan, Prince of Wales and Sydney Children's Hospital</i>	183	P59	Dermatomyositis. Underlying malignancy? <i>Simone Culleton, WA PET Service</i>			
252	P09	PiB imaging in posterior cortical atrophy: Is amyloidosis contributing to the neuropathology <i>Miceal McCarthy, Royal Perth Hospital</i>	164	P34	CT dose in SPECT/CT bone scans <i>Toby Beveridge, ARPANSA</i>	159	P60	F-18 FDG uptake in an ocular prosthesis- a rare finding on PET/CT <i>Nicole Kearney, Hunter New England Imaging</i>			
226	P10	The use of 18F-FDG PET/CT in status epilepticus - A case study <i>Schimmel Saleem, Austin Health</i>	242	P35	A fully integrated, cost effective and sophisticated capture system for radioactive gases generated during automated radiopharmaceutical synthesis <i>Damion Stimson, The Centre for Advanced Imaging</i>	234	P61	Two cases of Rhabdomyolysis: Pictorial review with a historical perspective <i>Kelvin Yap, St. Vincent's Hospital</i>			
173	P11	Seeing half the picture and difficulties in recall: Investigation of homonymous hemianopia and minimal cognitive impairment with stress and rest cerebral perfusion SPECT imaging <i>Paula Duong, Bankstown-Lidcombe Hospital</i>	231	P36	Design, construction and testing of a target cell for irradiation of powders using a cyclotron-generated proton beam: Application to TiO2 <i>Sun Chan, Sir Charles Gairdner Hospital</i>	125	P62	Neuroendocrine (carcinoid) tumour with unsuspected cardiac metastasis <i>Reza Garzan, The Prince Charles Hospital</i>			

- 225 **P12** Cerebral perfusion SPECT imaging in the investigation of visual obscuration and minimal cognitive impairment: A case study
Sarah Musgrave, Bankstown Lidcombe Hospital
- 240 **P13** Corticobasal degeneration, a rare neurodegenerative disorder diagnosed early with the help of cerebral perfusion SPECT imaging
Kristie Denmeade, Bankstown-Lidcombe Hospital
- 220 **P14** From Neurolite® to Ceretec® - A Major Headache
Nikki-Louise Scott, RBWH
- 230 **P15** 68Ga-DOTATATE PET/CT in conjunction with 99mTc-heat damaged RBC imaging - bringing back the old with the new
Jessica Bell, Hunter New England Imaging
- 206 **P16** Optimising the detection of colorectal cancer liver metastases with dynamic FDG PET acquisitions
Paul Thomas, Royal Brisbane and Women's Hospital
- 103 **P17** Comparison of double-input compartmental modelling and logan plot methods for metabolite correction in the analysis of dynamic PET data: A simulation study
Tong San Koh, National Cancer Centre Singapore
- 158 **P37** Lutetium-177 DOTATATE production for neuroendocrine tumour (NET) therapy with automated radiopharmaceutical synthesis system
Alireza Aslani, Royal North Shore Hospital
- 119 **P38** Optimized production and quality control of 68Ga-DOTATATE for small clinical trials
Amir R Jalilian, Radiation Application Research School
- 246 **P39** Use of the FlexLab radiosynthesisiser for the fully automated synthesis of 16?-[18F]fluoro-5?-dihydrotestosterone
Henri Tochon-Danguy, Austin Health
- 243 **P40** Fully automated production of Zr-89 using IBA Nirta and Pinctada Systems
Henri Tochon-Danguy, Austin Health
- 132 **P41** F-18 radiolabelling of DBCO as a synthon for copper free click chemistry using the FlexLab module
Henri Tochon-Danguy, Austin Health
- 209 **P42** Title: Automated system for cleaning and fast restarting of synthesizers
Gary Perkins, Australian Nuclear Science and Technology Organisation
- 115 **P63** Non-ossifying fibroma - an atypical presentation and bone scan appearance
Ramin Alipour, Bankstown-Lidcombe Hospital
- 198 **P64** Work-up of an incidental solitary liver lesion
Grace Rainbird, Bankstown Lidcombe Hospital
- 111 **P65** Rare case of Richter's transformation of chronic lymphocytic leukemia to Hodgkin's lymphoma demonstrated on FDG PET
Amir Iravani Tabrizipour, Nepean Hospital
- 169 **P66** An incidental diagnosis of thyroid cancer on a parathyroid study
Eilidh Wright, St FX Cabrini Hospital
- 241 **P67** A rare sight: Imaging necrotising fasciitis
Emma Brook, Royal Perth Hospital
- 244 **P68** Widespread periostitis due to acute syphilis: A case study
Elyse Langeluddecke, Queen Elizabeth Hospital

- 204 **P18** Does the use SUVmax uncertainty change by removing the Time of Flight (Non-ToF) reconstruction algorithm in [68Ga]-PSMA PET Imaging?
Elizabeth Bailey, Royal North Shore Hospital
- 223 **P19** Measurement of time-of-flight timing resolution for Philips Gemini TF64 / ingenuity TF128 PET/CT systems
Sylvia Gong, Austin Health
- 214 **P20** Use of direct intranodal injection of 99mTc-rhenium colloid for lymph node localisation: A case study
Bridget Chappell, Austin Health
- 247 **P21** Preoperative lymphoscintigraphic mapping for lymph node transfer in patients with postmastectomy lymphoedema
Amie Culverson, Sir Charles Gairdner Hospital
- 210 **P22** Concurrent low dose myocardial perfusion imaging (MPI), coronary artery calcium scoring (CACS) and CT coronary angiography (CTCA) in the management of coronary artery disease (CAD): Initial experience with an ultralow dose SPECT-CT scanner
Ramin Alipour, Bankstown-Lidcombe Hospital
- 224 **P23** The utility of MIBG scintigraphy in the diagnostic algorithm for patients with suspected pheochromocytoma - A tertiary hospital audit
Richard Gauci, Sir Charles Gairdner Hospital
- 145 **P43** Are turn-key radiopharmaceuticals trouble free?
Stephen Taylor, Royal Brisbane and Women's Hospital
- 245 **P44** Radiosynthesis and quality control of 68GA-DFO-UBI 29-41
William Hsieh, RAH Radiopharmacy
- 254 **P45** Titanium-45 as a candidate for PET Imaging: Cyclotron-based production and hydroxylamine-functionalized resin separation and purification
Roger Price, Medical Technology & Physics, Sir Charles Gairdner Hospital
- 138 **P46** Frequency of symptomatic gastroparesis (SG) post-lung transplantation (LTx)
Martin Cherk, The Alfred Hospital
- 250 **P47** Lutetium therapy - A review of patient responses to PRRT at the Queen Elizabeth Hospital
Jace Lawrie, Queen Elizabeth
- 181 **P48** Re-Treatment rates after low-dose radioactive iodine ablation for low-risk patients with thyroid cancer
Elizabeth Clingan, The St George Hospital Nuclear Medicine Department
- 179 **P69** Quality control of PET radiopharmaceuticals: Pgimer, Clinigam Experience,
Nitasha Garg, Ace Healthways Pty Ltd
- 235 **P70** Biodistribution of SIRspheres on 90Y-PET/CT vs. Bremsstrahlung SPECT/CT in patients with liver carcinoma
Wesley NG, Austin Health
- 197 **P71** Dosimetry of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian or Prostate Cancer
Sylvia Gong, Austin Health
- 221 **P72** The SLACK metric for validation of internal dosimetry for radionuclide therapy
Erin McKay, St. George Hospital
- 185 **P73** A Comparison of paediatric dose guidelines in nuclear medicine
Ingrid Holmes, Royal Brisbane and Women's Hospital
- 202 **P74** Radionuclide bone SPECT-CT: Lowering dose of CT significantly reduces radiation dose without impacting the image quality
Scott Trethewey, Hunter New England Health

- 162 **P24** High dose MIBG therapy under general anaesthesia in a 2yr old child
Catriona Green, The Children's Hospital at Westmead
- 136 **P25** 99mTc-labelled D-Glucosamine in the evaluation of disease activity in patients with ankylosing spondylitis and rheumatoid arthritis
Andrew Markewycz, Westmead Hospital
- 134 **P49** Severe pulmonary oedema; demonstrated on V/Q SPECT
Laura Renshaw, Hunter New England Imaging
- 133 **P50** Incidental finding of breast lesion onTc-99m MIBI myocardial perfusion imaging
Laura Renshaw, Hunter New England Health
- 131 **P51** Bone scintigraphy in the evaluation of acute mastoiditis in a confused patient
Jacqueline Behn, Bankstown-Lidcombe Hospital
- 127 **P75** Radiation exposure to the fingers of PET technologist's (PT's) at a major public hospital in Melbourne
Sarah Coleiro, Alfred Hospital Melbourne
- 128 **P76** Radiation doses to staff in the evolving world of nuclear medicine: Is radiation safety for staff being maintained?
James Turner, The Royal Brisbane & Women's Hospital
- 215 **P77** Radiation dose to nuclear medicine technologists: A 9 year review
Nicholas Forwood, Royal North Shore Hospital